EUCTR2022-000632-27-DK进行中（未招募）1 期
Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patients - PORT: Pragmatic Optimized Rifampicin trial
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 164
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The patient has a diagnosis of pulmonary tuberculosis according to the local diagnostic criteria.
- •The patient is aged 18 years or older at the day of informed consent.
- •No known allergic reactions or toxicity to rifampicin in the past.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 156
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •Patient infected with a rifampicin-resistant strain of M. tuberculosis.
- •The patient has TB meningitis.
- •The patient is in a coma.
研究者
相似试验
进行中（未招募）
1 期
Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patientsTuberculosisCTIS2023-509885-39-00Stichting Radboud University Medical Center130
尚未招募
3 期
Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patientstuberculosis10028440NL-OMON53704Radboud Universitair Medisch Centrum25
进行中（未招募）
1 期
High dose rifampicin for tuberculosis, PORTTuberculosisEUCTR2022-000632-27-NLRadboud University Medical Center164
未知
1 期
Phase 1 Study of BMS-986148Solid tumorsJPRN-jRCT2080223357Bristol-Myers Squibb K.K.15
未知
1 期
Study of BMS-986012 in Subjects With Small Cell Lung CanerSmall Cell Lung CancerJPRN-jRCT2080223369Bristol-Myers Squibb K.K.18